[go: up one dir, main page]

MX2018012687A - Fenitelaminas vinílogas como liberadores de neurotransmisores. - Google Patents

Fenitelaminas vinílogas como liberadores de neurotransmisores.

Info

Publication number
MX2018012687A
MX2018012687A MX2018012687A MX2018012687A MX2018012687A MX 2018012687 A MX2018012687 A MX 2018012687A MX 2018012687 A MX2018012687 A MX 2018012687A MX 2018012687 A MX2018012687 A MX 2018012687A MX 2018012687 A MX2018012687 A MX 2018012687A
Authority
MX
Mexico
Prior art keywords
monoamine
phenethylamines
vinylogous
activity
phenethylamine
Prior art date
Application number
MX2018012687A
Other languages
English (en)
Other versions
MX385064B (es
Inventor
Blough Bruce
Decker Ann
Rothman Richard
Original Assignee
Res Triangle Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Triangle Inst filed Critical Res Triangle Inst
Publication of MX2018012687A publication Critical patent/MX2018012687A/es
Publication of MX385064B publication Critical patent/MX385064B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/28—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by unsaturated carbon chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La descripción proporciona compuestos de inhibidor de capacitación de monoamina y/o liberador de neurotransmisores de monoamina que tienen actividad de transportador de amina, biogénico, pero que carecen de actividad sustancial en subtipos de receptor de 5-HT2. Los compuestos de fenetilamina viníloga o fenetilamina de la descripción son útiles para tratar enfermedades, condiciones y/o trastornos mediados por actividad de uno o más de los neurotransmisores de monoamina.
MX2018012687A 2016-05-12 2017-05-11 Fenitelaminas vinílogas como liberadores de neurotransmisores. MX385064B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662335191P 2016-05-12 2016-05-12
PCT/US2017/032143 WO2017197101A1 (en) 2016-05-12 2017-05-11 Vinylogous phenethylamines as neurotransmitter releasers

Publications (2)

Publication Number Publication Date
MX2018012687A true MX2018012687A (es) 2019-01-31
MX385064B MX385064B (es) 2025-03-11

Family

ID=60266721

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012687A MX385064B (es) 2016-05-12 2017-05-11 Fenitelaminas vinílogas como liberadores de neurotransmisores.

Country Status (9)

Country Link
US (1) US10899699B2 (es)
EP (1) EP3455203B1 (es)
JP (2) JP7073272B2 (es)
CN (1) CN109476583B (es)
AU (1) AU2017263457B2 (es)
CA (1) CA3022188A1 (es)
ES (1) ES2895773T3 (es)
MX (1) MX385064B (es)
WO (1) WO2017197101A1 (es)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541228A (en) * 1994-10-14 1996-07-30 Bristol-Myers Squibb Co. Melatonergic agents
KR100510794B1 (ko) * 1997-02-04 2005-08-31 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 살진균 카르복스아미드
US6337351B1 (en) 1998-10-22 2002-01-08 Targacept, Inc. Pharmaceutical compositions and methods for use
US6262124B1 (en) 1998-10-22 2001-07-17 Gary Maurice Dull Pharmaceutical compositions and methods for use
US7084154B2 (en) 2003-02-11 2006-08-01 Pharmacopeia Drug Disclovery, Inc. 2-(aminomethyl) arylamide analgesics
ATE495165T1 (de) * 2004-09-30 2011-01-15 Boehringer Ingelheim Int Alkynilbasierte derivate von benzophenonen als nichtnukleoside reverse-transkriptase-inhibitoren
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
CL2007002105A1 (es) * 2006-07-21 2008-02-22 Hoffmann La Roche Compuestos derivados de 2-[3-(3-cianofenoxi)(fenoxi o fenilsulfanil)]-n-fenil acetamida, inhibidores de la transcriptasa inversa del vih; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar u
JP5420534B2 (ja) 2007-05-31 2014-02-19 サノビオン ファーマシューティカルズ インク モノアミン再取り込み阻害薬としてのフェニル置換シクロアルキルアミン
CN102170874A (zh) * 2008-08-06 2011-08-31 高思福斯中心（控股）有限公司 治疗精神病学障碍的组合物和方法
US8367660B2 (en) 2008-12-30 2013-02-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP2419400A1 (en) 2009-04-15 2012-02-22 Research Triangle Institute Monoamine reuptake inhibitors
PL2455371T3 (pl) * 2009-07-16 2014-05-30 Sds Biotech Corp Pochodne 4-(3-butynylo)aminopirymidyny jako środki do zwalczania szkodników do stosowania w rolnictwie i ogrodnictwie
SI2281801T1 (sl) * 2009-07-27 2014-04-30 Crystal Pharma, S.A.U. Postopek za pridobivanje 3,3-diphenilpropilamina
WO2011103189A1 (en) * 2010-02-16 2011-08-25 Uwm Research Foundation, Inc. Methods of reducing virulence in bacteria
CA2824573A1 (en) 2011-01-14 2012-07-19 Sds Biotech K.K. Agri-horticultural pest control compositions comprising 4-(3-butynyl)aminopyrimidine derivatives
WO2013048982A1 (en) * 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
RU2015129065A (ru) * 2012-12-17 2017-01-25 Пэрион Сайенсиз, Инк. Производные хлор-пиразинкарбоксамида, обладающие активностью блокирования эпителиальных натриевых каналов
US20160022636A1 (en) * 2013-03-14 2016-01-28 Janssen Pharmaceutica Nv Physiological ligands for gpr139

Also Published As

Publication number Publication date
CA3022188A1 (en) 2017-11-16
US10899699B2 (en) 2021-01-26
MX385064B (es) 2025-03-11
JP2022101537A (ja) 2022-07-06
JP2019520311A (ja) 2019-07-18
EP3455203A1 (en) 2019-03-20
EP3455203A4 (en) 2019-11-13
CN109476583A (zh) 2019-03-15
AU2017263457A1 (en) 2018-11-15
ES2895773T3 (es) 2022-02-22
JP7343641B2 (ja) 2023-09-12
US20190225573A1 (en) 2019-07-25
EP3455203B1 (en) 2021-09-22
CN109476583B (zh) 2025-09-23
WO2017197101A1 (en) 2017-11-16
AU2017263457B2 (en) 2021-07-08
JP7073272B2 (ja) 2022-05-23

Similar Documents

Publication Publication Date Title
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
MX2017005457A (es) Metodos y compuestos agonistas de gip.
CY1123007T1 (el) Υποκατεστημενα 4-αζαϊνδολια και χρηση αυτων ως ρυθμιστες υποδοχεα glun2b
MX2017014375A (es) Moduladores del ccr2.
CL2018001899A1 (es) Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock)
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
IL290992A (en) Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22q syndrome
PL3660004T3 (pl) Związki i sposoby do ukierunkowanej degradacji receptora androgenowego
UY34832A (es) TIAZOLES SUSTITUIDOS POR CARBOXAMIDA O SULFONAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUÉRFANO RORy (lambda)
MX2018004290A (es) Compuestos, composiciones y metodos para modular el regulador de la conductancia transmembrana de la fibrosis quistica.
CO2019003162A2 (es) Formas cristalinas y salinas de compuestos agonistas de ppar
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
DK3294738T3 (da) Mono- og disubstituerede indolderivater som inhibitorer af replikation af denguevirus
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
SV2018005613A (es) Agentes, usos y metodos para el tratamiento
MX2018000778A (es) Metodos para tratar trastornos mediados por hepcidinas.
BR112016026544A2 (pt) métodos para inibir a necroptose
BR112019010131A2 (pt) entrega transdérmica de agentes grandes
CL2016002084A1 (es) Compuestos derivados de ciclopentano 1,2 substituidos como antagonistas del receptor de orexina.
CL2019001426A1 (es) Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f.
MX374654B (es) Compuestos útiles para inhibir ror-gamma-t.
CL2016002267A1 (es) Ureas asimétricas p-sustituidas y usos médicos de las mismas
BR112015010475A2 (pt) composição granular de limpeza de superfícies, mistura de limpeza e método para limpeza de uma superfície
MX2016014166A (es) Compuestos de triaminopirimidina utiles para evitar o tratar la malaria.
BR112015009996A2 (pt) composição granular de limpeza de superfícies, mistura de limpeza e método para limpeza de uma superfície